Follow Us GraphicFacebook IconTwitter IconLinkedIn Icon
Search Graphic

Expert Financial Analysis and Reporting

Antares; My View of How Otrexup and Medacís New Product Rasuvo May Compete (ATRS, Buy, $2.54)

Investors Are Concerned About Rasuvoís Impact on Otrexup

Investors have been concerned about the potential effect on Otrexup if the private…
Read more…

Antares (ATRS, Buy, $4.00) Why I Think That the Otrexup Launch Will Be A Success (Paid Subscribers Only)

Recent Price Behavior

Antaresí (ATRS) price has drifted down since the approval of Otrexup for the treatment of rheumatoid arthritis and…
Read more…